|
|||||
|
|
The prognostic value of 18F-FDG PET/CT taken immediately after completion of radiotherapy for lung cancer treated with concurrent chemoradiotherapy: A pilot study |
|
| Affiliation: | 1. Clinical training center, Juntendo university, Urayasu hospital, 2-1-1 Tomioka Urayasushi, Chiba, Japan;2. Department of radiation oncology, Juntendo university, faculty of medicine, Tokyo, Japan;3. Department of radiology, Juntendo Tokyo Koto geriatric medical center, Tokyo, Japan;4. Department of respiratory medicine, Juntendo university, Urayasu hospital, Chiba, Japan;1. Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte d’Azur, 33, avenue de Valombrose, 06189 Nice, France;2. Department of Neurosurgery, Centre Hospitalier Universitaire de Nice, Nice, France;3. Department of Endocrinology, Centre Hospitalier Universitaire de Nice, Nice, France;4. Department of Biostatistics, Centre Antoine-Lacassagne, Nice, France;5. Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King''s College, London, UK;6. UCL Institute of Ophthalmology, University College London, London, UK;7. Department of Internal Medicine, CHU de La Réunion, 97400 Saint Denis, France;1. Radiation Oncology Department, La Pitié-Salpétrière university hospital, AP–HP, Paris, France;2. Radiation Oncology Department, CHU Lyon Sud, HCL, Lyon, France;3. Institut Curie, Radiation Oncology Department, Paris & Proton Center, Orsay, France;1. Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, 300, Guangzhou Road, Gulou District, Nanjing, Jiangsu, China;2. Department of Radiation Oncology, Nanjing Jiangning Hospital and the Affiliated Jiangning Hospital of Nanjing Medical University, 168, Gushan Road, Jiangning District, Nanjing, Jiangsu, China;3. Department of Radiation Oncology, The Second Hospital of Nanjing, 1-1, Zhongfu Road, Gulou District, Nanjing, Jiangsu, China |
| Abstract: | PurposeThe prognostic value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) taken immediately after completion of radiotherapy in lung cancer patients is not well known. The purpose of this study is to assess the prognostic value of PET/CT taken immediately after completion of radiotherapy in lung cancer patients.Materials and methodsPatients with primary lung cancer planned to undergo concurrent chemoradiotherapy were enrolled. Patients underwent PET/CT scans at 3 time points: before radiotherapy, within 24 hours of completing radiotherapy (im-PET/CT), and 2–9 months after radiotherapy (post-PET/CT). Maximum standardized uptake value (SUVmax) was obtained. A post-PET/CT-SUVmax cut-off of 2.5 was determined as radiotherapy success.ResultsNineteen patients were enrolled. im-PET/CT-SUVmax for patients in the high post-PET/CT-SUVmax group was significantly higher than that of the low group (P = 0.004). Receiver operator curve analysis indicated that im-PET/CT-SUVmax of 4.35 was an optimal cut-off value to discriminate between the two groups. Multivariable analysis showed that a high im-PET/CT-SUVmax was significantly associated with a high post-PET/CT-SUVmax (P = 0.003).ConclusionPET/CT-SUVmax taken immediately following radiotherapy was associated with that evaluated 2–9 months after radiotherapy. |
| Keywords: | F-18 fluorodeoxyglucose positron emission tomography/computed tomography Non-small cell lung cancer SUVmax Concurrent chemoradiotherapy Tomographie par émission de positons/tomographie par ordinateur au fluorodésoxyglucose F-18 Cancer du poumon non à petites cellules SUVmax Chimioradiothérapie simultanée |
| 本文献已被 ScienceDirect 等数据库收录！ | |
